Chargement de l’entreprise
Keep exploring
The themes China SXT Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B $USA
NBIXNeurocrine Biosciences, Inc.16,9B $USA+
ELANElanco Animal Health Incorporated13,4B $USA
KNSAKiniksa Pharmaceuticals International, plc8,2B $USA+
LQDALiquidia Corporation5,2B $USA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Comment elle gagne de l'argent
- Regular traditional Chinese medicine pieces95 %
- Advanced traditional Chinese medicine pieces4 %
Les parts du chiffre d'affaires sont des estimations pour year ended March 31, 2026, pas des chiffres tirés d'un document officiel.
En concurrence avec
- 600518Kangmei Pharmaceutical Co., Ltd.
- 300147Xiangxue Pharmaceutical Co., Ltd.
Ce qu'elle vend6
Regular traditional Chinese medicine pieces
Medicinal plants processed into forms such as cut pieces or powders, generally prepared by boiling or decoction before use.
Directly-Oral advanced TCMP
Processed herbal medicines made to be taken by mouth without first being boiled as a decoction.
After-Soaking-Oral advanced TCMP
Small sealed bags of herbal material steeped in hot water to make an infusion.
Afficher 3 de plus
SanQiFen
A directly swallowed powder made from the roots and rhizomes of notoginseng.
CuYanHuSuo
A directly swallowed powder made from the tubers of Corydalis yanhusuo.
LuXueJing
A directly swallowed product made from dried deer blood.
Qui l'achète3
- Hospitals, especially traditional Chinese medicine hospitals, buy products for patient care, mainly in Jiangsu province.
- Pharmaceutical wholesalers buy products and distribute them to hospitals and other healthcare distributors.
- As of March 31, 2026, end customers included 46 pharmaceutical companies, 11 chain pharmacies and 12 hospitals (March 31, 2026, high).
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1Relies on medicinal-plant raw materials supplied by vendors in China.
- 2Relies on a limited number of customers; hospitals and pharmaceutical distributors account for important sales channels.
- 3Its business in China depends on contractual arrangements with Taizhou Suxuantang, a variable interest entity, rather than direct ownership of that operating company.
Ce qui pourrait mal tourner
- 1Losing or reducing sales to a small number of major customers could harm revenue.
- 2Disruptions in the supply of medicinal plants or other raw materials could interrupt production and deliveries.
- 3The company may be unable to enforce its contractual arrangements with Taizhou Suxuantang, or changes in Chinese rules may affect those arrangements or its ability to operate.
À propos de China SXT Pharmaceuticals, Inc.
China SXT makes traditional Chinese medicine pieces (TCMP) from medicinal plants, including herbs prepared as powders and other forms. In the fiscal year ended March 31, 2026, regular TCMP made up 95.02% of revenue (FY2026, high), while advanced TCMP made up 4.35% (FY2026, high); some advanced products can be swallowed directly or steeped in hot water. Total revenue was $1,138,052 (year ended March 31, 2026, high).
- Siège
- Taizhou, Jiangsu, China
- Fondée en
- 2017
- Effectif
- 56 full-time employees (March 31, 2026, high)
- Cotée sur
- Nasdaq Capital Market
- Clôture de l'exercice
- March 31
Construit à partir des documents déposés par China SXT Pharmaceuticals, Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
